Safety and tolerability of rifaximin for the treatment of irritable bowel syndrome without constipation: a pooled analysis of randomised, double‐blind, placebo‐controlled trials

BACKGROUND: The efficacy of rifaximin, a nonsystemic, gut‐targeted antibiotic for reducing non–constipation‐predominant irritable bowel syndrome (non‐C IBS) symptoms, has been demonstrated in one phase 2b and two phase 3 randomised, double‐blind, placebo‐controlled trials, but detailed data about ri...

Descripción completa

Detalles Bibliográficos
Autores principales: Schoenfeld, P., Pimentel, M., Chang, L., Lembo, A., Chey, W. D., Yu, J., Paterson, C., Bortey, E., Forbes, W. P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley-Blackwell 2014
Materias:
Irritable Bowel Syndrome
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4112801/
https://www.ncbi.nlm.nih.gov/pubmed/24697851
http://dx.doi.org/10.1111/apt.12735

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4112801/
https://www.ncbi.nlm.nih.gov/pubmed/24697851
http://dx.doi.org/10.1111/apt.12735

Ejemplares similares